Daniel Alkon

Daniel Alkon

Company: Synaptogenix

Job title: President –Research


Uncovering Bryostatin Targets Restoration of Synaptic Wiring Lost in Alzheimer’s Degeneration 2:00 pm

Investigating actual cognitive improvement over baselines measured in initial placebo-controlled clinical trials Hearing evidence for sustained benefit for weeks after drug regimens have been in trialled Showcasing targets including synaptic growth factors, the apoptosis pathway, as well as amyloid and neurofibrillary tanglesRead more

day: Track B - Day 1 PM

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.